Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.41 |
| ▸ | PIM1 | P11309 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980701 | 0.85 | UBE2M (0.40) | ALDH1A1SMN1; SMN2HCRTR1HCRTR2PIM1 | |
| SCHEMBL925007 | 0.82 | KDM4E (0.63) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL983342 | 0.81 | KDM4E (0.46) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL983083 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL30775082 | 0.81 | HCRTR1 (0.52) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL269010 | 0.81 | HCRTR1 (0.52) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL980832 | 0.80 | SLC6A3 (0.55) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL924869 | 0.80 | KDM4E (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL984311 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL27824198 | 0.78 | ALOX5 (0.43) | ALDH1A1SMN1; SMN2HCRTR1HCRTR2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318367-B1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8288435-B2 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8236801-B2 | 2-aza-bicyclo[2.2.1]heptane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-2247586-B1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-26 | — | — | US | disclosed |
| EP-2318367-A1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-11 | — | — | EP | disclosed |
| EP-2094690-B1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20110039857-A1 | PIPERIDINE AND PYROOLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2247586-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| EP-2155739-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009133522-A1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-05 | — | — | WO | disclosed |
| EP-2094690-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009104155-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
| WO-2008139416-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008081399-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CNR1 | KDM4E 1064/4885ALDH1A1 807/4885HPGD 854/4885 |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | KDM4E 2641/4885ALDH1A1 937/4885HPGD 1868/4885 |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | HCRTR2, HCRTR1, HCAR2 | KDM4E 933/4885ALDH1A1 532/4885HPGD 869/4885 |
| US-20110039857-A1 | PIPERIDINE AND PYROOLIDINE COMPOUNDS | HCRTR1, HCRTR2, NPY1R | KDM4E 954/4885ALDH1A1 1189/4885HPGD 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.